Patents by Inventor Mainul Hoque

Mainul Hoque has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10254409
    Abstract: A device and a method determine a sample point specific vertical total electronic content which is the electron content along a sample point specific vertical path that extends through the center of the earth and the sample point. A first inclined total electronic content is determined and refers to the electron content along an inclined beam path. A first and a further sample point along the beam path are selected. An initial sample point specific vertical total electronic content is determined for each sample point. An increment electron content is determined and refers to the electron content of the increment associated with the sample point. A further inclined total electronic content is determined. A sample point specific conversion function is determined. The sample point specific vertical total electronic content is determined from the first inclined total electronic content and the sample point specific conversion function.
    Type: Grant
    Filed: September 15, 2014
    Date of Patent: April 9, 2019
    Assignee: Deutsches Zentrum fuer Luft- und Raumfahrt e.V.
    Inventors: Norbert Jakowski, Mohammed Mainul Hoque
  • Patent number: 9849146
    Abstract: Provided are methods for treating a NAD comprising administering to a patient suffering from a NAD an inhibitor of NMD and a nonsense suppressor, whereby degradation of NMD susceptible mRNA is decreased and translation termination at a misplaced nonsense codon is blocked.
    Type: Grant
    Filed: June 13, 2012
    Date of Patent: December 26, 2017
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Tsafi Pe'ery, Michael B. Mathews, Mainul Hoque, Hartmut M. Hanauske-Abel
  • Publication number: 20170319612
    Abstract: Provided are methods for treating a NAD comprising administering to a patient suffering from a NAD an inhibitor of NMD and a nonsense suppressor, whereby degradation of NMD susceptible mRNA is decreased and translation termination at a misplaced nonsense codon is blocked.
    Type: Application
    Filed: June 13, 2012
    Publication date: November 9, 2017
    Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Tsafi Pe'ery, Michael B. Mathews, Mainul Hoque, Hartmut M. Hanauske-Abel
  • Patent number: 9271998
    Abstract: Provided are methods for treating a NAD comprising administering to a patient suffering from a NAD a composition comprising an eIF5A inhibitor compound in an amount effective to prevent intracellular hypusination of eIF5A, whereby gene expression of NMD-susceptible mRNA is increased.
    Type: Grant
    Filed: November 18, 2013
    Date of Patent: March 1, 2016
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Tsafi Pe'ery, Michael B. Mathews, Mainul Hoque, Hartmut M. Hanauske-Abel
  • Publication number: 20140329700
    Abstract: The invention relates to compositions and methods to isolate nucleic acids, and the identification of polyadenylation sites in a gene of interest. In one aspect, the invention provides an oligonucleotide comprising at least one nucleic acid and an affinity moiety, wherein said nucleic acid is 30-60 nucleotides in length and said nucleic acid comprises 1-25 uracil and 5-50 thymine nucleotides.
    Type: Application
    Filed: August 23, 2012
    Publication date: November 6, 2014
    Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Bin Tian, Wenting Luo, Zhe Ji, Mainul Hoque
  • Publication number: 20140206637
    Abstract: Provided are methods for treating a NAD comprising administering to a patient suffering from a NAD an inhibitor of NMD and a nonsense suppressor, whereby degradation of NMD susceptible mRNA is decreased and translation termination at a misplaced nonsense codon is blocked.
    Type: Application
    Filed: June 13, 2012
    Publication date: July 24, 2014
    Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Tsafi Pe'ery, Michael B. Mathews, Mainul Hoque, Hartmut M. Hanauske-Abel
  • Publication number: 20140073685
    Abstract: Provided are methods for treating a NAD comprising administering to a patient suffering from a NAD a composition comprising an eIF5A inhibitor compound in an amount effective to prevent intracellular hypusination of eIF5A, whereby gene expression of NMD-susceptible mRNA is increased.
    Type: Application
    Filed: November 18, 2013
    Publication date: March 13, 2014
    Applicant: Rutgers, The State University of New Jersey
    Inventors: Tsafi Pe'ery, Michael B. Mathews, Mainul Hoque, Hartmut M. Hanauske-Abel
  • Publication number: 20120225093
    Abstract: The present invention relates to compositions and methods of treating, inhibiting, or controlling HIV infection.
    Type: Application
    Filed: October 11, 2011
    Publication date: September 6, 2012
    Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY
    Inventors: Michael B. Mathews, Hartmut M. Hanauske-Abel, Tsafi Pe'ery, Mainul Hoque, Paul Palumbo, Deepti Saxena, Darlene D'Alliessi-Gandolfi, Myung-Hee Park
  • Publication number: 20120095058
    Abstract: The present invention discloses compounds and pharmaceutical compositions which are highly effective at inhibiting the accumulation of spliced and unspliced viral transcripts and their utilization for viral protein synthesis at cellular ribosomes, and at inhibiting the formation of the hypusine residue in cellular eIF-5A precursor proteins, the cellular cofactors that render spliced and unspliced viral transcripts translatable at the ribosomes of infectled cells. The invention further relates to methods of using such compounds and pharmaceutical compositions therefrom for inhibiting or preventing viral protein synthesis. Such inhibition cause a dose-dependent release from the virally induced arrest of the otherwise genetically preprogrammed apoptosis of virally infected cells, and in consequence, triggers their apoptotic ablation and the eradication of the chronic infection-mediating provirus integrated into their genome.
    Type: Application
    Filed: December 1, 2004
    Publication date: April 19, 2012
    Inventors: H., M. Hanauske-Abel, Paul Palumbo, B., M. Cracchiolo, Myung-Hee Park, Edith Wolff, Axel-Rainer Hanauske, Michael B. Mathews, Deepti Saxena, Mainul Hoque
  • Publication number: 20110039911
    Abstract: Provided are methods for treating a NAD comprising administering to a patient suffering from a NAD a composition comprising an eIF5A inhibitor compound in an amount effective to prevent intracellular hypusination of eIF5A, whereby gene expression of NMD-susceptible mRNA is increased.
    Type: Application
    Filed: July 20, 2010
    Publication date: February 17, 2011
    Inventors: Tsafi Pe'ery, Michael B. Mathews, Mainul Hoque, Hartmut Martin Hanauske-Abel